Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


German Pricing Mechanism Adds Weak Economies, Could Spell Trouble For EU Industry

This article was originally published in The Pink Sheet Daily

Executive Summary

The decision by the German pharmaceutical arbitration committee to include countries such as Greece in a final pricing mechanism will cut German prices and may have a Europe-wide effect.

You may also be interested in...

IQWiG’s First Cost-Effectiveness Review Could Take Drug HTA To New Frontiers

Germany’s reimbursement watchdog IQWiG’s first cost-effectiveness analysis uses four antidepressants as test case and finds they are overpriced.

AstraZeneca’s Brilique Triumphs As First Drug Through Germany’s New Pricing Process

Following negotiations, AstraZeneca’s clot buster Brilique has been awarded a price that has pleased both the manufacturer and health insurers – but industry as a whole remains skeptical of the system.

Big Pharma Insiders Pessimistic About Pricing Going Forward

Pricing and market access continue to be trends that plague big pharma, even as patent expirations and lagging new drug launches create harder circumstances for companies.

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts